Generative AI (GenAI) poses significant cybersecurity risks, including adversarial attacks, data privacy concerns, and potential misuse. GenAI can be manipulated, leading to misinformation, breaches, and reputational damage. To mitigate these risks, organisations must enhance model transparency, enforce rigorous testing, ensure compliance with data regulations, and maintain human oversight, particularly in critical decision-making processes.
SHARE :
This Excel document is part of the company profiles PAC publishes every year at local, regional and worldwide level.
Event Date : December 12, 2024
This Excel document is part of the company profiles PAC publishes every year at local, regional and worldwide level.
Event Date : June 21, 2023
This Excel document is part of the company profiles PAC publishes every year at local, regional and worldwide level; it includes the following ...
Event Date : April 05, 2024
The Cloud Computing vendor profiles portray leading providers of cloud computing, analyzing their strategies and portfolios.
Event Date : April 17, 2024
This document provides market volumes, growth rates and forecasts for the Public and Hosted Private Cloud in China for the 2022-2028 period.
Event Date : February 13, 2024
Kyndryl - Figures - Austria - FY 31 - Mar - 25
Datamart July 08, 2025
Kyndryl – Vendor Profile – Austria
Vendor Profile July 08, 2025
IBM - Figures - Austria - FY 31 - Dec - 24
Datamart July 08, 2025
IBM – Vendor Profile – Austria
Vendor Profile July 08, 2025
Kyndryl - Figures - Spain - FY 31- Mar - 25
Datamart July 07, 2025
Atos: Cause for Optimism, Despite the Headlines
Blog Post February 05, 2024
Factory digitalization in small & medium-sized industrial companies
Whitepaper & Trend Studies July 10, 2025
Part 6: Navigating the OT Security Market – Tools, Services, and Providers
Blog Post July 10, 2025
Capgemini acquires WNS: Accelerating the arms race for operating model reimagination
Blog Post July 08, 2025
Research Note: Fujitsu Strategy Summit
Blog Post July 08, 2025
Part 5: Quantum Use Cases by Industry – Part 3: Pharma & Chemistry
Blog Post July 04, 2025